. ABBY: A phase 2 randomized trial of crenezumab in mild to moderate Alzheimer disease. Neurology. 2018 May 22;90(21):e1889-e1897. Epub 2018 Apr 25 PubMed.


Please login to recommend the paper.


  1. The data presented provides another important and interesting advance in understanding the relationship between biomarkers and potential cognitive changes in Alzheimer’s disease. The authors nicely demonstrated dose dependent biomarker effects on soluble A and also provide tantalizing results of a potential cognitive signal. The cognitive signal suggests a larger effect at earlier stages of the disease, but is limited due to the exploratory analysis of this Phase 2 study. Anticipation is high for this and other drugs at higher doses in both symptomatic and prevention trials. The field is actively addressing the “too little” challenge.

Make a Comment

To make a comment you must login or register.

This paper appears in the following:


  1. Crenezumab


  1. On Target: Crenezumab Reduces Aβ Oligomers in CSF